Vapotherm (VAPO) Downgraded by Zacks Investment Research to Sell

Zacks Investment Research cut shares of Vapotherm (NYSE:VAPO) from a hold rating to a sell rating in a research report sent to investors on Saturday.

According to Zacks, “Vapotherm Inc. is a medical technology company. It designs and develops respiratory devices for the treatment of chronic lung and acute breathing disorders. The Company provides flow vapor transfer cartridges, delivery tubes and disinfection kits. Vapotherm Inc. is based in Exeter, New Hampshire. “

A number of other research firms have also weighed in on VAPO. Canaccord Genuity boosted their price objective on shares of Vapotherm from $22.00 to $27.00 and gave the company a buy rating in a research report on Wednesday. BTIG Research began coverage on shares of Vapotherm in a research report on Monday, December 10th. They issued a buy rating for the company. William Blair reissued an outperform rating on shares of Vapotherm in a research report on Monday, December 10th. Finally, Bank of America began coverage on shares of Vapotherm in a research report on Monday, December 10th. They issued a buy rating and a $26.00 price objective for the company. One analyst has rated the stock with a sell rating and four have issued a buy rating to the stock. Vapotherm has an average rating of Buy and an average price target of $26.50.

Shares of VAPO opened at $20.00 on Friday. The stock has a market cap of $334.64 million and a price-to-earnings ratio of -1.45. Vapotherm has a 12-month low of $14.70 and a 12-month high of $22.07.

Vapotherm (NYSE:VAPO) last announced its earnings results on Tuesday, March 12th. The company reported ($1.28) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.40) by $0.12. The business had revenue of $11.69 million for the quarter, compared to analyst estimates of $11.00 million. Equities analysts expect that Vapotherm will post -2.7 EPS for the current year.

Several large investors have recently bought and sold shares of the company. Perceptive Advisors LLC acquired a new position in shares of Vapotherm in the fourth quarter valued at approximately $24,464,000. Lord Abbett & CO. LLC acquired a new position in shares of Vapotherm in the fourth quarter valued at approximately $7,573,000. BlackRock Inc. acquired a new position in shares of Vapotherm in the fourth quarter valued at approximately $6,248,000. Pura Vida Investments LLC acquired a new position in shares of Vapotherm in the fourth quarter valued at approximately $2,984,000. Finally, Northern Trust Corp acquired a new position in shares of Vapotherm in the fourth quarter valued at approximately $1,156,000. 47.51% of the stock is owned by institutional investors and hedge funds.

Vapotherm Company Profile

Vapotherm, Inc, a medical technology company, focuses on the development and commercialization of proprietary Hi-VNI technology products used to treat patients of various ages suffering from respiratory distress worldwide. The company offers precision flow systems, such as Precision Flow Plus, Precision Flow Classic, and Precision Flow Heliox that use Hi-VNI technology to deliver heated, humidified, and oxygenated air at a high velocity to patients through a small-bore nasal interface.

Featured Story: Bollinger Bands

Get a free copy of the Zacks research report on Vapotherm (VAPO)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Vapotherm Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vapotherm and related companies with MarketBeat.com's FREE daily email newsletter.